85%Confidence
0Views
FDASource
2026-03-31Date
Summary
Cipla's Nilotinib Capsules recall due to stability test failures indicates potential quality control issues at their Goa facility, which could impact supply of this oncology drug and damage brand reputation. This may create opportunities for competitors in the tyrosine kinase inhibitor market but also raises concerns about manufacturing oversight in the pharmaceutical supply chain.
Actionable: Monitor Cipla's manufacturing compliance reports and consider diversifying oncology drug sourcing to mitigate supply chain risks.
AI Confidence: 85%
Data Points
firmCipla USA, Inc.
classificationClass III
statusOngoing
distributionU.S.A. Nationwide
productNilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now